Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novelix PharmaceuticalsBOM:536565 -1.56%61 Days Payable is 160.41 as of Mar. 2026, which is 294% above its 10-year median of 40.71. GuruFocus rates BOM:536565 with a GF Score™ of 61/100 and a GF Value™ of ₹145.67 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 116 Medical Distribution companies, Novelix Pharmaceuticals ranks better than 59.48% on this metric.
The historical rank and industry rank for Novelix Pharmaceuticals's Days Payable or its related term are showing as below:
BOM:536565'
s Days Payable Range Over the Past 10 Years
Min: 2.7 Med: 40.71 Max: 969.22
Current: 91.26
During the past 13 years, Novelix Pharmaceuticals's highest Days Payable was 969.22. The lowest was 2.70. And the median was 40.71.
BOM:536565's Days Payable is ranked better than 59.48% of 116
companies
in the Medical Distribution industry
Industry Median: 79.46
vs BOM:536565: 91.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:536565 vs MCK, CAH, COR: Days Payable Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Novelix Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals (BOM:536565) has a Days Payable of 160.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novelix Pharmaceuticals and its competitors. This is 294% above median its historical median of 40.71. Over the past decade, Novelix Pharmaceuticals' Days Payable has ranged from 2.70 to 969.22. According to the industry distribution chart, Novelix Pharmaceuticals ranks #47 out of 116 companies in the Medical Distribution industry, placing it in the top 40.5%.
Is Novelix Pharmaceuticals' Days Payable too high?
Novelix Pharmaceuticals' current Days Payable of 160.41 is 294% above median its 10-year median of 40.71. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 969.22. The Medical Distribution industry median Days Payable is 79.46. Novelix Pharmaceuticals' value of 160.41 is 101.9% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #47 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Novelix Pharmaceuticals has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #47 out of 116 companies for Days Payable. This puts Novelix Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 79.46. Novelix Pharmaceuticals' value of 160.41 is 101.9% above this benchmark. Historically, Novelix Pharmaceuticals' own Days Payable has ranged from 2.70 to 969.22 over the past decade. While the company's 10-year median is 40.71 vs. the industry median of 79.46, Novelix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.46, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current Days Payable of 160.41 is 101.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Days Payable is 79.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current Days Payable is 160.41, which is 294% above median its own 10-year median of 40.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹145.67, compared to a current price of ₹70.65 — trading 51.5% below its estimated fair value. The current Days Payable is 160.41, which is 294% above median its 10-year median of 40.71 and 101.9% above the Medical Distribution industry median of 79.46. Novelix Pharmaceuticals' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Days Payable is 160.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?
Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹70.65 is trading 51.5% below its estimated GF Value™ of ₹145.67.
GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for BOM:536565:
Days Payable: 160.41 (294% above median its 10-year median of 40.71)
GF Value™: ₹145.67 vs. price of ₹70.65 (51.5% below fair value)
Industry Position: 101.9% above the Medical Distribution median (#47 of 116)
No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
61GF Score
Get the complete analysis for BOM:536565
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
